Why the study?
Does NLRP3 gene silencing ameliorate diabetic cardiomyopathy in a type 2 diabetes rat model?
Does NLRP3 gene silencing ameliorate diabetic cardiomyopathy in a type 2 diabetes rat model?
NLRP3 silencing ameliorates DCM in diabetic rats; hypothesis-generating and leaves open translation to humans.
Background: Nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome is associated with metabolic disorder and cell death, which are important triggers in diabetic cardiomyopathy (DCM). We aimed to explore whether NLRP3 inflammasome activation contributes to DCM and the mechanism involved.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: